Thoracic Pathology Course 2025

Co-sponsored by Memorial Sloan Kettering Cancer Center (MSK) and Massachusetts General Hospital (MGH), and endorsed by the Pulmonary Pathology Society (PPS), this course offers a comprehensive review of thoracic pathology with clinical and radiologic correlations.

The program features expert-led lectures, in-depth discussions, and case presentations on thoracic tumors, along with a multidisciplinary session dedicated to non-neoplastic lung diseases. Anticipated changes in the next WHO Classification of Lung Tumors, the 9th Edition TNM Staging Classification, the new 2025 ATS/ERS Classification of Interstitial Pneumonias and Guidelines for Diagnosis of Hypersensitivity Pneumonitis will be presented.

While the majority of faculty are expert lung pathologists, the course also includes presentations from distinguished thoracic clinicians and radiologists. Together, these sessions highlight the importance of a multidisciplinary approach in addressing complex challenges in thoracic disease.

The course will be held at Memorial Sloan Kettering Cancer Center on Manhattan’s Upper East Side—a vibrant, safe neighborhood with convenient access to New York City’s renowned cultural attractions. For details on travel and lodging, please visit the Accommodations tab above. A virtual attendance option is also available for those who are unable to join us in person.

Target Audience: This course is designed for pathologists, pulmonologists, thoracic surgeons, and radiologists, including residents and fellows in training.

Post-course Resources: Following the course, registrants will receive access to a syllabus that includes PDF versions and recorded videos of faculty presentations.

1. Discuss the current concepts in lung, pleural and mediastinal pathology
2. Apply clinically relevant advances and technology in molecular pathology of lung cancer
3. Describe the importance of correlation between clinical, radiologic and pathologic data in diagnosis and management of interstitial lung disease
4. Identify the significance of lung biopsy and multidisciplinary correlation for the diagnosis of non-neoplastic lung disease with a focus on interstitial pneumonias, hypersensitivity pneumonitis and acute lung injury
5. Implement the most recent histologic concepts in lung cancer diagnosis and classification including problematic issues related to spiral CT screening
6. Apply the differential diagnosis for mediastinal and pleural lesions
7. Correlate the usefulness of cytology in pulmonary, pleural and mediastinal diagnoses

This course offers the option to attend either in person or virtually. Attendance type should be selected during registration.

Early Rates (available through September 5)

• Physicians (MDs, DOs, PhDs): $795

• Pathology Assistants, Fellows, Residents, RNs, and Other Healthcare Providers: $350

• Industry Professionals*: not available (general rates apply)

• MSK Employees: Complimentary

General Rates (after September 5)

• Physicians (MDs, DOs, PhDs): $895

• Pathology Assistants, Fellows, Residents, RNs, and Other Healthcare Providers: $450

• Industry Professionals*: $1,550

• MSK Employees: Complimentary

*An “industry professional” is defined as any individual—regardless of profession (e.g., MD, PhD, APP, RN)—who is employed by an ineligible company. View our Registration Policy for Industry Professionals for more information.

Registration Discounts: Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

Meals and Accommodations: Continental breakfast, lunch, and refreshment breaks will be provided to in-person participants. If you have dietary restrictions or require special accommodations to attend in person, please contact us at [email protected] at least one week prior to the course.

Cancellation Policy: For details on our cancellation terms, please review our Cancellation Policy.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 15.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPath CC Recognition Statement

This activity will offer 15.50 Lifelong Learning (CME) credit towards the American Board of Pathology’s Continuing Certification program.

We look forward to welcoming you to Memorial Sloan Kettering Cancer Center (MSK).

If you’ll be traveling to New York City from out of town, we recommend that you plan your overnight stays as soon as possible. To make the planning a little easier, MSK has negotiated special rates and amenities at select hotels in Manhattan. Click here to view the list of select hotels and additional details on each.

For details on planning your visit to MSK, including travel and parking information, click here. Please note that parking validation is not available for attendees.

If you require any specific accommodations to attend this event in person, please contact [email protected] at least one week in advance.

Course Directors

William D. Travis, MD
Director, Thoracic Pathology
Attending, Department of Pathology and Laboratory Medicine 
Memorial Sloan Kettering Cancer Center 

Mari Mino-Kenudson, MD
Director, Pulmonary Pathology
Pathologist, Massachusetts General Hospital
Professor of Pathology, Harvard Medical School

Course Co-Directors

Natasha Rekhtman, MD, PhD 
Attending, Department of Pathology and Laboratory Medicine 
Memorial Sloan Kettering Cancer Center 

Lida P. Hariri, MD, PhD
Pathologist, Massachusetts General Hospital
Associate Professor of Pathology, Harvard Medical School

Course Faculty

Marina K. Baine, MD, PhD
Assistant Attending
Department of Pathology and Laboratory Medicine 
Memorial Sloan Kettering Cancer Center

Mary B. Beasley, MD
Professor of Pathology, Molecular and Cell Based Medicine
Mount Sinai School of Medicine

Alain Charles Borczuk, MD 
Chairman, Department of Pathology, of Pathology and Laboratory Medicine 
Long Island Jewish Medical Center
Chairman, Department of Pathology, of Pathology and Laboratory Medicine 
North Shore University Hospital
Professor, Donald and Barbara Zucker School of Medicine
Hofstra/Northwell

Jason Chang, MD
Assistant Attending
Department of Pathology and Laboratory Medicine 
Memorial Sloan Kettering Cancer Center

Sanja Dacic, MD, PhD
Professor of Pathology
Vice Chair and Director of Anatomic Pathology
Yale School of Medicine 

Robert Jeffrey Kaner, MD
Attending Physician
NewYork-Presbyterian Hospital
Professor of Clinical Medicine and Genetic Medicine
Weill Cornell Medical College

Marc Ladanyi, MD
Chief Attending, Molecular Diagnostics Service
William J. Ruane Chair in Molecular Oncology
Department of Pathology and Laboratory Medicine 
Memorial Sloan Kettering Cancer Center

Alan C. Legasto, MD
Assistant Attending Radiologist
NewYork-Presbyterian Hospital
Assistant Professor of Clinical Radiology
Weill Cornell Medical College

Andre L. Moreira, MD, PhD
Professor, Department of Pathology, NYU Grossman School of Medicine 
Director, NYU Center for Biospecimen Research and Development
Director, Cardiopulmonary Pathology Fellowship Program
Director, Surgical Pathology
Director, Pulmonary Pathology
NYU Langone

Maelle Saliba, MD
Assistant Professor of Pathology 
NewYork-Presbyterian Hospital
Weill Cornell Medical College

Anjali Saqi, MD, MBA
Professor of Pathology & Cell Biology at CUMC
Director, Pulmonary Pathology
NewYork-Presbyterian / Columbia University Irving Medical Center

Fang Zhou, MD
Clinical Associate Professor, Department of Pathology
NYU Grossman School of Medicine 
Director, Informatics, Anatomic Pathology
NYU Langone

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.